Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure

Description

Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.

Conditions

Obesity, Obesity, Morbid, Obesity, Primary, Metabolic Disease, Delayed Gastric Emptying Following Procedure

Talk to us

Study Overview

On this page

Study Details

Study overview

Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.

Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure: A Pilot Study

Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * subjects must be 18-70 years of age
  • * eligible for endoscopic and surgical weight loss procedures
  • * body mass index (BMI) greater than 35 kg/m2
  • * Individuals must be in excellent mental health
  • * able to understand and sign informed consent
  • * available to return for all routine follow-up study visits
  • * untreated H. pylori infection
  • * gastroparesis
  • * active smoking
  • * an ongoing or a history of treatment with opioids in the last 12 months prior to enrollment
  • * previous pyloromyotomy or pyloroplasty
  • * gastrointestinal obstruction
  • * severe coagulopathy
  • * esophageal or gastric varices and/or portal hypertensive gastropathy
  • * pregnancy or puerperium
  • * any inflammatory disease of the gastrointestinal tract (including but not limited to severe (LA Grade C or D) esophagitis, active gastric ulceration, active duodenal ulceration, or specific inflammation such as Crohn's disease)
  • * malignant or premalignant gastric diseases (such as high grade dysplasia, gastric cancer, or GIST)
  • * severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)
  • * lactation
  • * history of gastrointestinal surgery
  • * any serious health condition unrelated to their weight that would increase the risk of endoscopy
  • * chronic abdominal pain
  • * active psychological issues preventing participation in a lifestyle modification program
  • * a known history of endocrine disorders affecting weight (uncontrolled hypothyroidism)
  • * an inability to provide informed consent
  • * use of any medication that may interfere with weight loss
  • * use of any medication that may interfere with gastric emptying
  • * any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Christopher C. Thompson, MD, MSc,

Christopher C. Thompson, MD, MSc, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Study Record Dates

2024-12-31